What does this company do and how does it make money?

Gilead operates as a pharmaceutical company with extreme concentration in HIV treatments, where its flagship drug Biktarvy dominates market share. The company invests heavily in R&D to diversify beyond HIV, but after years of effort, non-HIV products still represent only 20% of revenue.

Five legendary investment frameworks analyzed this company.

Buffett sees a moat at 86.8% gross margins while Marks sees disaster in 377-day inventory — but why did stock compensation drop to zero for the first time in company history? Tap any framework below to explore their complete analysis and discover what each legend would do with this pharmaceutical puzzle.

How much cash does it generate and where does it go?

Gilead generates robust cash flows but allocated capital poorly, destroying $4.7 billion in shareholder value through buybacks at prices 79% above current levels. The zero stock compensation in Q4'25 represents an unprecedented 3.78 standard deviation drop from historical norms, suggesting either extreme confidence or accounting adjustments.

Is the business getting stronger or weaker?

Surface metrics show a business recovering from Q1'24's one-time charge with strong margins, but working capital efficiency collapsed dramatically in Q4'25. The 268% spike in inventory days and 275% increase in cash conversion cycle suggest operational stress that headline profitability metrics don't capture.

What could go wrong and has it survived trouble before?

Gilead's extreme HIV concentration creates binary risk — any competitive threat or regulatory change could devastate 80% of revenue. The 25.5x operating leverage means small revenue declines become earnings disasters, yet insiders are selling while the balance sheet shows peak liquidity, suggesting they see trouble ahead that strong financials currently mask.

Days inventory outstanding exploded from 102 to 377 days in one quarter while institutions accumulated to 87.7% ownership — someone is wrong about what's building up in those warehouses.

Is the stock priced for perfection, fair value, or pessimism?

The market prices Gilead for dramatic acceleration, requiring 26% perpetual growth to justify its premium to risk-free rates — an impossibility for a mature pharma company growing at 2.4%. The wide analyst target range and asymmetric earnings reactions reveal deep uncertainty about whether current profitability can overcome HIV concentration risks.